These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28123126)

  • 1. [Efficacy and safety of long-term bisphosphonate treatment for osteoporosis.].
    Miki T
    Clin Calcium; 2017; 27(2):239-246. PubMed ID: 28123126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates].
    Moro Álvarez MJ; Neyro JL; Castañeda S
    Med Clin (Barc); 2016 Jan; 146(1):24-9. PubMed ID: 26048545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
    Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
    J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety issues with bisphosphonate therapy for osteoporosis.
    Suresh E; Pazianas M; Abrahamsen B
    Rheumatology (Oxford); 2014 Jan; 53(1):19-31. PubMed ID: 23838024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who will benefit from antiresorptive treatment (bisphosphonates)?
    Papapoulos SE
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate use after clinical fracture and risk of new fracture.
    Bergman J; Nordström A; Nordström P
    Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
    Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
    Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men.
    Brown SA; Guise TA
    Nat Clin Pract Urol; 2007 Jun; 4(6):310-20. PubMed ID: 17551535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination and sequential therapy using bisphosphonates.].
    Okazaki R
    Clin Calcium; 2017; 27(2):263-271. PubMed ID: 28123129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.
    Rossini M; Orsolini G; Viapiana O; Adami S; Gatti D
    Endocrine; 2015 Aug; 49(3):620-7. PubMed ID: 25649760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance.
    Lloyd AA; Gludovatz B; Riedel C; Luengo EA; Saiyed R; Marty E; Lorich DG; Lane JM; Ritchie RO; Busse B; Donnelly E
    Proc Natl Acad Sci U S A; 2017 Aug; 114(33):8722-8727. PubMed ID: 28760963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.
    Grover M; Bachrach LK
    Curr Osteoporos Rep; 2017 Aug; 15(4):271-282. PubMed ID: 28620868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A; Ito M
    Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.